Details for Patent: 9,228,187

Which drugs does patent 9,228,187 protect, and when does it expire?

Patent 9,228,187 protects AMONDYS 45 and is included in one NDA.

This patent has sixty patent family members in twenty-two countries.

Summary for Patent: 9,228,187

Title:	Antisense molecules and methods for treating pathologies
Abstract:	An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.
Inventor(s):	Stephen Donald Wilton, Sue Fletcher, Abbie Adams, Penny Meloni
Assignee:	University of Western Australia
Application Number:	US14/108,137
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,228,187
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 9,228,187

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes	9,228,187		Y	Y

Foreign Priority and PCT Information for Patent: 9,228,187

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	2009905549	Nov 12, 2009

International Family Members for US Patent 9,228,187

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010317599
Australia	2016202924
Australia	2018202105
Australia	2020260498
Australia	2023203103
Australia	2025271352